ABAlaa F. Badawi

Alaa F. Badawi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alaa F. Badawi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate

    by Alaa F. Badawi, Yingying Liu, Mazen B. Eldeen, Willard Morrow, Zaineb R. Razak, Marie Maradeo, Mostafa Z. Badr

    Senescence-associated changes in the prostate are believed to play an important role in the genesis of prostate cancer. In order to provide further information on how aging increases the prostate susceptibility to cancer, we examined the pattern of cyclooxygenase (COX)-2 expression and the concomitant alterations in prostaglandin E 2 (PGE 2 ) synthesis in the prostate glands of 4-, 10-, 50- and 100-week-old Fischer 344 rats. This was carried out in the prostatic areas where hormone-induced tumors arise, namely the periurethral ducts of the dorsolateral prostate (DLP). Age-associated changes were also evaluated for pro- and anti-apoptotic factors linked to COX-2 signaling and known to be involved in the normal development of the prostate gland as well as in carcinogenesis. COX-2 expression was increased in the DLP in an age-dependent manner where senescent rats had >3–4-fold higher COX-2 mRNA and protein levels than their juvenile counterparts ( P 2 synthesis. Evaluation of mediators of apoptotic signaling showed a significant ( P 6-fold) and peroxisome proliferator-activated receptor γ (>3-fold) and in caspase-3 activity (>2-fold) and an up-regulation of the anti-apoptotic Bcl 2 (>8-fold), PKCα (>2-fold) and pAkt (>4-fold) in the 100-week-old rats versus the 4-week-old animals. There was an ∼15-fold age-dependent decrease in the pro-apoptotic ratio BAX:Bcl 2 and an increase in the anti-apoptotic variable PKCα * Bcl 2 /BAX in the senescent rats compared with the juvenile ones. These results suggest that increased COX-2 expression can be linked to the decline in the pro-apoptotic signaling in the prostate gland during aging. Subsequently, COX-2 inhibitors can be considered as a promising class of agents to attenuate the increased cell survival and, hence, protect against tumorigenesis in the aging prostate.


  • Retracted
    Open Access

    Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor γ

    by Alaa F. Badawi, Mazen B. Eldeen, Yingying Liu, Eric A. Ross, Mostafa Z. Badr

    We examined the effect of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, and N-(9-fluorenyl-methyloxycarbonyl)-l-leucine (F-l-Leu), a peroxisome proliferator-activated receptor γ (PPARγ) agonist, separately and combined, on the development of methylnitrosourea (MNU)-induced rat mammary gland carcinogenesis. Celecoxib and F-l-Leu significantly reduced tumor incidence and multiplicity (P < 0.05). Combining both agents exerted higher (synergistic) cancer inhibition than separate treatments (P < 0.05). The effects of the test drugs on COX-2 and PPARγ expression and on the synthesis of prostaglandin E2 (PGE2) and 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) were examined in rat mammary normal (MNU-untreated), uninvolved, and tumor (MNU-treated) tissues. Celecoxib and F-l-Leu, separately, inhibited COX-2 and up-regulated PPARγ expression. These effects were paralleled by inhibition of PGE2 synthesis and up-regulation of 15d-PGJ2. Combined treatment resulted in higher alterations in COX-2 and PPARγ transcripts and PG synthesis compared with separate administrations. The effect of the test agents on Bcl2, BAX, and protein kinase Cα expression levels were examined in the rat mammary gland and the pro-(BAX:Bcl2) and anti-[PKCα*(Bcl2/BAX)] apoptotic ratios were evaluated. Each drug increased the proapoptotic ratio by 2- to 7-fold and reduced the antiapoptotic ratio by 2- to >8-fold in all tissues. Combined treatment, however, resulted in >9- to 14-fold up-regulation in the proapoptotic processes and 15- to >30-fold down-regulation in the antiapoptotic ones. Analyses were also carried out on the drug-induced modulation of cell cycle regulators and proliferation markers (cyclin-dependent kinase 1 and proliferating cell nuclear antigen). F-l-Leu and celecoxib each reduced the cyclin-dependent kinase 1 and proliferating cell nuclear antigen expression in the tumor. Higher down-regulation was attained in all tissues by combined treatment where cyclin-dependent kinase 1 and proliferating cell nuclear antigen almost retained the expression levels observed in the normal glands. In conclusion, simultaneous targeting of COX-2 and PPARγ may inhibit mammary cancer development more effectively than targeting each molecule alone. COX-2 inhibitors and PPARγ agonists coordinately mediate their anticancer effect via both COX-dependent (inhibition of COX-2, activation of PPARγ, and modulation PG synthesis) and COX-independent (induction of proapoptotic factors and inhibition of cell proliferation) pathways.


  • Expression of cyclooxygenase‐2 and peroxisome proliferator‐activated receptor‐γ and levels of prostaglandin E2 and 15‐deoxy‐Δ12,14‐prostaglandin J2 in human breast cancer and metastasis

    by Alaa F. Badawi, Mostafa Z. Badr

    Cyclooxygenase‐2 (COX‐2) expression and peroxisome proliferator‐activated receptor‐γ (PPARγ) inactivation are linked to increased risk of human breast cancer. The purpose of our study was to examine the relationship between COX‐2 (with the resulting prostaglandins E2, PGE2) and PPARγ (and its natural endogenous ligand 15‐Deoxy‐Δ12,14‐prostaglandin J2, 15d‐PGJ2) at various stages during the development of human breast cancer and its progression to metastasis. Human breast tissue specimens were collected from normal breasts or from individuals with fibrocystic disease and served as controls (n = 22). Tissues were also collected from uninvolved (n = 25), tumor (n = 25) and lymph node metastasis (n = 15) regions from breast cancer patients. COX‐2 and PPARγ mRNA expression were increased and downregulated, respectively, in tissues from cancer patients compared to controls. Metastatic tissues tended to have higher alterations compared to non‐metastatic tissues (p < 0.05). These altered expressions in COX‐2 and PPARγ were paralleled by increases in the tissue levels of PGE2 and decreases in 15d‐PGJ2. A significant inverse correlation was found between PGE2 and 15‐d‐PGJ2 (r = −0.51, p < 0.05). Significant correlations (p < 0.05) were also obtained between COX‐2 and PPARγ mRNA (inverse, r = −0.72) and between COX‐2 and PGE2 (direct, r = 0.68). Increases in COX‐2 mRNA expression and levels of PGE2 and down‐regulation of PPARγ mRNA expression and 15d‐PGJ2 levels were characterized as predictors of breast cancer risk (p < 0.05). Our results suggest that the altered expression of COX‐2 and PPARγ and the subsequent modulation in the tissue levels of PGE2 and 15‐d‐PGJ2 may influence the development of human breast cancer and its progression to metastasis.


  • Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ (Review)

    by Alaa F. Badawi, Mostafa Z. Badr

    Cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptor-γ (PPARγ) have emerged as candidate molecules that hold great promise for cancer chemoprevention. COX-2 increased expression and PPARγ inactivation occur during mammary gland carcinogenesis. COX-2 and PPARγ may contribute to breast cancer induction either directly or via their effects on factors known to influence tumor development, e.g., nuclear factor-κB and vascular endothelial growth factor. Inhibition of COX-2 or activation of PPARγ prevents mammary carcinomas in experimental animals with little toxicity. Combinational treatment with COX-2 inhibitor and PPARγ agonists may produce synergistic anti-tumorigenic effects without significant toxicity and, therefore, be an effective strategy to prevent human breast cancer. Establishing a relationship between COX-2 and PPARγ in this malignancy may provide the basis for a novel chemopreventive strategy based on the modulation of both molecules simultaneously. This review evaluates experimental and epidemiological findings suggesting a possible role of COX-2 and PPARγ in the development of human breast cancer and presents evidence substantiating their coordinated action in carcinogenesis and finally develops a rationale for the simultaneous targeting of both molecules as a potentially effective strategy to prevent breast malignancy.


  • Influence of Cigarette Smoking on Prostaglandin Synthesis and Cyclooxygenase-2 Gene Expression in Human Urinary Bladder Cancer

    by Alaa F. Badawi, Samy L. Habib, Mohammed A. Mohammed, Ahmed A. Abadi, Michael S. Michael

    The present study examines the effect of tobacco smoking on the expression of cyclooxygenase (COX)-2 gene, COX enzymatic activity and prostaglandin (PG) synthesis in urothelial mucosal tissues from...